Update on Redemption Process
Source: RNS
BELLEVUE HEALTHCARE TRUST PLC (the "Company")
LEGAL ENTITY IDENTIFIER ('LEI'): 213800HQ3J3H9YF2UI8
14 October 2024
UPDATE ON REDEMPTION PROCESS
As per its announcement on 30 July 2024, the Company has a redemption facility through which shareholders are entitled to request the redemption of all or part of their holding of ordinary shares on an annual basis.
The total number of ordinary shares as of the record date, in respect of which Redemption Requests were received for the 22 November 2024 Redemption Point was 163,834,887 (representing 36.34% of the Company's issued share capital (excluding treasury shares)).
The Directors have decided to calculate the Redemption Price by reference to the amount generated upon the realisation of a Redemption Pool created for the purpose of funding the redemption. Hence the portfolio will be split into a Redemption Pool and a Continuing Pool from the close of business today. Daily Net Asset Value announcements published from tomorrow will reflect the Continuing Pool.
The Board has engaged a third party to undertake sanctions checking and continues to validate all redemption requests received.
A further announcement will be made by the Company for the redeeming shareholders shortly after the 2024 Redemption Point setting out the redemption details.
Defined terms in the announcement have the same meaning as set out in the Articles of Association, a copy of which may be obtained from the Company Secretary.
Enquiries:
|
J.P. Morgan Cazenove |
|
William Simmonds, Rupert Budge |
|
Telephone: +44 (0)20 3493 8000 |
|
|
|
NSM Funds (UK) Limited |
|
Brian Smith, Ciara McKillop |
|
Telephone: +44 (0)20 3697 5770 |
|
|
|
H/Advisors Maitland |
|
William Clutterbuck |
|
Telephone: +44 (0) 7785 292 617 |
|
|
|
Bellevue Asset Management (UK) Ltd. |
|
Mark Ghahramani |
|
Telephone: +44 (0)20 3326 2981 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
